Anaphylaxis to Stinging Insect Venom.
Allergy
Anaphylaxis
Hymenoptera
Immunotherapy
Insect
Stinging
Venom
Journal
Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
5
1
2022
Statut:
ppublish
Résumé
Hymenoptera stinging insects are common culprits for allergic reactions. Anaphylaxis to insect stings can be life threatening and is associated with a significant risk of recurrence. Insect allergy requires referral to an allergist/immunologist for education and for diagnostic evaluation that will direct further management and treatment. Venom immunotherapy is safe and effective; it prevents sting anaphylaxis in up to 98% of patients. Potential risk factors for side effects during testing and treatment should be assessed for every patient to mitigate risk and to guide treatment recommendations and the duration of immunotherapy.
Identifiants
pubmed: 34823745
pii: S0889-8561(21)00078-3
doi: 10.1016/j.iac.2021.09.003
pii:
doi:
Substances chimiques
Arthropod Venoms
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-173Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Disclosure K.E. Adams has nothing to disclose. J.M. Tracy serves on the advisory boards for Pharming, Biocrist, and Thermo-Fischer; Honoraria: UptoDate. D.B.K. Golden serves on the speaker bureau for Genentech; as a consultant to ALK, Stallergenes, Allergy Therapeutics, Kaleo, and Aquestive; as a section editor for UpToDate and receives clinical trials support from Genentech, Novartis, and Allergy Therapeutics.